This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G11.3 | Special Copayment Reduction: V123 |
| B. Synonyms | Cerebellar ataxia with defective DNA repair, ataxia-telangiectasia [Louis-Bar], Louis-Bar syndrome |
| C. Adult onset | Possibility of first onset in adulthood very low — onset in childhood (1–3 years), loss of ability to walk in the teens, early death common |
| 1. History | 1926 first description by Louis-Bar, 1988 ATM gene location identified, 1995 ATM gene cloned |
| 2. Causes | Mutations in the ATM gene (11q22.3) cause loss of ATM kinase function and defective DNA double-strand break repair |
| 3. Genetics | Autosomal recessive, carrier frequency about 1/100, increased risk of cancer (especially breast cancer) in carriers |
| 4. General epidemiology | Prevalence about 1/40,000–1/100,000, rare worldwide, equal in males and females |
| 5. Pathophysiology | ATM deficiency → DNA DSBs not detected or repaired → abnormal cell cycle checkpoints → vulnerability of neural, immune, and vascular cells |
| 6. Symptoms | Progressive cerebellar ataxia, cutaneous and conjunctival telangiectasia, immunodeficiency (IgA and IgG2 deficiency), cancer predisposition, radiosensitivity |
| 7. Signs | Signs of cerebellar ataxia, conjunctival telangiectasia, eye movement abnormalities (oculomotor apraxia), signs of immunodeficiency |
| 8. Screening | Elevated AFP, immunoglobulin deficiency, chromosomal instability testing, ATM gene testing |
| 9. Diagnosis | ATM gene sequencing, Western blot for ATM protein expression, radiosensitivity testing, confirmation of elevated AFP |
| 10. Treatment | No curative treatment; immunoglobulin replacement, antibiotic prophylaxis, cancer surveillance, minimizing radiation exposure, rehabilitation therapy |
| 11. Prognosis | Most lose the ability to walk in their teens; average life expectancy around 25 years (cancer and infection are the main causes of death); improved survival in some with mild mutation types |
| 12. Prevention | Genetic counseling, carrier testing, prenatal diagnosis, minimizing exposure to radiation and carcinogens, infection prevention |
| 13. References | Savitsky K et al. Science 1995 and 9 other papers |
The clinical description of ataxia-telangiectasia (A-T) began in 1926, when the Belgian neurologist Denise Louis-Bar first reported a child with both cerebellar ataxia and cutaneous and conjunctival telangiectasia. The syndrome subsequently also came to be called 'Louis-Bar syndrome'. In the 1950s, Boder and Sedgwick reported familial cases, establishing it as a hereditary disease.
In the 1960s–70s, immunodeficiency and cancer predisposition were identified as important features of this disease. In particular, it was confirmed that patients show hypersensitive reactions to radiation therapy and radiological examinations, suggesting a link to defective DNA damage repair. In 1988, the location of the ATM gene was narrowed to the long arm of chromosome 11 (11q22-23), and in 1995 Savitsky et al. cloned the ATM (Ataxia Telangiectasia Mutated) gene, elucidating the pathogenesis at the molecular level.
After the discovery of the ATM gene, ATM kinase was shown to be the key protein in recognizing DNA double-strand breaks (DSB) and became established as a core element of the signaling pathways that regulate cell cycle checkpoints, DNA repair, and apoptosis. ATM kinase is now an important target of cancer biology and radiobiology research, and the finding that breast cancer risk is also increased in A-T carriers (heterozygotes) has further heightened its clinical importance.
The cause of A-T is homozygous or compound heterozygous mutations of the ATM gene located on the long arm of chromosome 11 (11q22.3). The ATM gene encodes ATM kinase, which belongs to the PI3 kinase-like protein kinase (PIKK) family, and is a large gene consisting of 66 exons. Mutation types are diverse, including nonsense, frameshift, splice-site mutations, and missense mutations, and in 80–90% of all alleles the ATM protein is completely lost (null mutation).
Normally, when a DNA double-strand break (DSB) occurs, ATM kinase receives signals from the MRN complex (MRE11-RAD50-NBS1), is rapidly activated, and phosphorylates numerous substrate proteins. Through H2AX histone phosphorylation, activation of CHK1 and CHK2 kinases, p53 stabilization, and the like, it arrests the cell cycle and activates DNA repair pathways, or induces apoptosis when damage is excessive. When ATM function is lost, none of these processes work, so DNA damage accumulates and cells become extremely sensitive to radiation and chemotherapy.
Patients with mild mutations (hypomorphic mutations, leaky splice site variants, etc.) retain some residual ATM protein function and may present with an atypical phenotype showing later onset, slower progression, and longer survival.
A-T is an autosomal recessive genetic disorder. Disease develops only when loss-of-function mutations are present in both ATM alleles. The frequency of ATM mutation carriers (heterozygotes) in the worldwide population is relatively high, at about 1/100. Carriers do not develop A-T, but carriers of heterozygous ATM mutations have a 2–4-fold increased risk of cancer, particularly breast cancer. This means that the possibility of ATM carrier status should be considered clinically when investigating a family history of breast cancer.
For A-T patients, only carrier status is passed on to their children (because the patient is homozygous). When both parents are carriers, 25% of their children are affected. Siblings have a 25% chance of being affected and a 50% chance of being carriers. In genetic counseling, these risks should be clearly communicated, and enhanced cancer surveillance may be recommended for carrier siblings.
The ATM gene is very large (about 150 kb in total, mRNA about 13 kb) and mutations are distributed widely throughout the entire gene, so whole-gene sequencing is required for diagnostic genetic analysis. Founder mutations are known in certain ethnic groups and regions (e.g., Israeli Jews, Arabs), so targeted testing can be performed first.
The worldwide prevalence of A-T is estimated at about 1/40,000–1/100,000. Higher prevalence due to founder effects has been reported in certain ethnic groups (e.g., Israeli Arabs 1/30,000). Prevalence in Asia, including Korea, is known to be similar to or slightly lower than in Europe, but accurate domestic statistics are lacking.
Onset occurs in childhood in almost all cases, with gait ataxia appearing around age 1–2 when the child first begins to walk, or in early childhood (age 2–3). The male-to-female ratio is equal. The incidence of new cases is estimated at about 1/100,000/year. Registration and management as a rare disease in Korea is done under Special Copayment Reduction code V123, and this disease is included among patients seen in pediatric neurology and pediatric immunology.
Because the A-T carrier frequency is relatively high at about 1/100, the increased cancer risk in carriers has major public health significance beyond families in which A-T occurs. In particular, there is growing recognition that heterozygous ATM mutations should be included as a moderate-risk gene in breast cancer genetic counseling.
Defective repair of DNA double-strand breaks (DSBs) due to ATM deficiency is the core mechanism of A-T. In normal cells, when a DNA DSB occurs, ATM is rapidly activated (phosphorylated) and cooperates with the MRN complex to phosphorylate H2AX histones around the damaged site (γH2AX formation), and activates cell cycle checkpoints to halt cell division. ATM regulates all of the G1/S, S-phase, and G2/M checkpoints via CHK1 and CHK2, and phosphorylates and stabilizes p53 to induce apoptosis.
Without ATM, none of these processes work, so cell division proceeds with unrepaired DNA damage and genomic instability accumulates. Cerebellar Purkinje cells and granule cells experience particularly many programmed DSBs during V(D)J recombination in development, making them especially vulnerable to ATM deficiency. T and B lymphocyte development also depends on V(D)J recombination, so immunodeficiency results.
Telangiectasia of the skin and conjunctiva is thought to result from vascular endothelial cell damage caused by radiation injury or oxidative stress that cannot be repaired because of ATM deficiency. The predisposition to cancers such as lymphoma and leukemia arises because programmed DSBs during lymphocyte development and sporadic oncogenic mutations are not repaired due to ATM deficiency. Radiosensitivity is due to the failure of ATM-dependent DNA repair pathways.
A-T is a multisystem disorder involving the nervous system, blood vessels, immune system, and a predisposition to tumors. The first symptom is progressive cerebellar ataxia appearing at age 1–3 after the child begins to walk. Gait instability, balance impairment, and limb incoordination gradually worsen. Ocular motor abnormalities accompany the disease from a very early stage, characteristically oculomotor apraxia (difficulty initiating voluntary saccades).
Telangiectasia of the skin and conjunctiva usually begins to appear at age 3–6 and gradually progresses. It starts in the conjunctiva and spreads to the ears, neck, and flexural areas of the limb joints. Immunodeficiency commonly involves IgA, IgG2, and IgE deficiency, and T lymphocyte function is also reduced, so respiratory infections such as recurrent pneumonia and sinusitis are common. Chronic lung disease and bronchiectasis may develop from recurrent infections.
Cancer risk is markedly elevated, with lymphoma (especially B-cell lymphoma) and leukemia (T-cell ALL) being the most common. Cancer develops in about 30–40% of all A-T patients, and the risk exists from childhood. Endocrine abnormalities (hypogonadism, growth impairment, insulin resistance), a premature aging phenotype, and skin pigmentation abnormalities have also been reported. Cognitive function is often relatively preserved, but some patients have mild intellectual disability.
Neurological examination reveals signs of cerebellar ataxia (limb incoordination, gait instability, dysarthria). Characteristically, oculomotor apraxia is present, with a compensatory behavior of turning the head first in order to initiate voluntary saccades. This is a highly specific sign of A-T.
Conjunctival examination shows prominent telangiectasia, usually clearly visible in both conjunctivae after age 4–6. Skin examination also shows telangiectasia around the ears and nose and in the flexural areas of the elbows and knees. Hypotonia and decreased or absent deep tendon reflexes are present. Pyramidal signs are not prominent early on but develop in some patients. Endocrine examination may reveal delayed puberty and abnormal sexual maturation.
On laboratory testing, serum alpha-fetoprotein (AFP) is markedly elevated in most A-T patients (generally far exceeding normal adult reference values), making it an important biomarker of A-T. Immunoglobulin testing shows decreased IgA, IgG2, and IgE. Chromosome studies cytogenetically confirm spontaneous chromosomal instability and increased radiosensitivity. A mild elevation of serum CEA is also observed.
Early screening for A-T should be prompted by the combination of progressive cerebellar ataxia in childhood + recurrent respiratory infections + oculomotor apraxia. Serum AFP measurement is the simplest and most sensitive screening test. A-T is suspected if AFP levels remain abnormally high after age 2 (usually far exceeding age-specific normal levels) or if there is a persistent elevation of 10 IU/mL or more.
Immunoglobulin measurement (IgA, IgG subclasses, IgE, IgM) and lymphocyte subset analysis (T and B cell counts, T cell function) are needed to assess immunodeficiency. Chromosomal instability testing (spontaneous chromosome breakage, increased chromosome damage after irradiation) supports the diagnosis. ATM protein expression analysis (Western blot) confirms loss or marked reduction of ATM protein. If all these tests are normal, A-T is excluded and other causes of cerebellar ataxia are considered.
Siblings of A-T patients in the family are identified early through ATM genetic testing. Enhanced surveillance for cancer (especially breast cancer) is recommended for carrier family members (parents). When prenatal diagnosis is needed during pregnancy, the fetal ATM gene is analyzed by chorionic villus sampling or amniocentesis.
A-T is confirmed by whole ATM gene sequencing identifying loss-of-function mutations in both alleles. Because the ATM gene is large, NGS-based panel testing or clinical exome sequencing is efficient. Testing first for founder mutations known in specific ethnic groups is also efficient. Whether a mutation is pathogenic must be confirmed by functional studies or literature evidence.
Supporting diagnostic tests include confirmation of loss or marked reduction of ATM protein by Western blot, abnormal elevation of serum AFP, immunodeficiency (IgA deficiency in 95%), and inability of cells to repair DNA damage after irradiation with a G2/M checkpoint defect. Serum AFP is a useful biomarker for A-T screening but cannot confirm the diagnosis on its own.
Brain MRI shows progressive cerebellar atrophy, particularly prominent in the cerebellar hemispheres and vermis. Chest CT is needed to evaluate recurrent pneumonia and bronchiectasis. Immune function assessment evaluates lymphocyte subsets, T cell proliferative responses, and antibody production capacity. Regular testing for malignancy surveillance (abdominal ultrasound, lymph node palpation, complete blood count) is needed.
There is currently no curative treatment for A-T; the goal of treatment is to prevent complications and maintain function through multisystem management. For immunodeficiency, intravenous or subcutaneous immunoglobulin replacement therapy (IVIG/SCIG) according to the degree of IgA/IgG deficiency is the core treatment. Prophylactic antibiotics (amoxicillin-clavulanate, etc.) are used to prevent recurrent pneumonia. When lung function is reduced, bronchodilators, mucolytics, and chest physiotherapy are provided.
In cancer treatment, A-T patients are extremely sensitive to radiation and certain chemotherapy agents (DNA cross-linking agents, topoisomerase inhibitors), so standard-dose treatment can be fatal. Radiation therapy is in principle contraindicated, and chemotherapy also requires dose reduction. Antibody therapy (rituximab, etc.) and immunotherapy are preferred. The potential for synthetic lethality with PARP inhibitors and ATR inhibitors in ATM-deficient tumors is being studied.
Rehabilitation (physical, occupational, and speech therapy) is important for maintaining function in all patients. Radiation exposure (X-rays, CT scans) should be minimized as much as possible, with MRI used preferentially. Neuroprotective effects of antioxidants, amantadine, minocycline, and corticosteroids have been suggested in small studies, but the level of evidence is still low. Gene therapy and exon-skipping research aimed at restoring ATM kinase activity is under way at the preclinical stage.
Overall, A-T has a very poor prognosis. Most patients lose the ability to walk in their teens and require a wheelchair. Average life expectancy was previously known to be around 25 years, but with improved management of immunodeficiency and prevention of complications, survival into the 30s–40s is now reported in some patients.
The main causes of death are cancer (especially lymphoma and leukemia, in about 30–40% of patients) and respiratory failure due to recurrent infections. In patients who develop cancer, treatment options are limited, so the prognosis is very poor. Patients with atypical A-T who have mild mutations (some residual ATM function preserved) may show much slower progression and longer survival. Aggressive immunoglobulin replacement, infection prevention, and cancer surveillance can significantly improve prognosis.
Because A-T is an autosomal recessive genetic disorder, when both parents are ATM carriers, 25% of their children are affected. Genetic counseling can accurately communicate the recurrence risk, and transmission of the pathogenic allele can be prevented through preimplantation genetic testing (PGT-M) or prenatal diagnosis. Siblings have a 25% risk of being affected and a 50% risk of being carriers, so they are identified early through genetic testing.
For family members who are ATM carriers (heterozygotes), enhanced surveillance for the increased risk of cancers such as breast cancer (regular mammography, MRI screening, etc.) is recommended. For A-T patients themselves, radiation exposure (including diagnostic radiological tests) should be minimized, using the minimum dose only when clinically necessary. Vaccination is essential, although live vaccines (MMR, varicella, etc.) should be decided carefully according to the immunodeficiency status, and pneumococcal, influenza, and Haemophilus vaccines are recommended. Regular pulmonary function testing and early treatment of respiratory infections are important for preventing pulmonary complications.